The World Health Organisation has defined pharmacovigilance as "The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drug-related problem."
In this episode, we're discussing adverse drug event prevention and the study of pharmacovigilance with pharmacist and researcher Dr. Sara Rogers, PharmD, BCPS.
Listen along as we review:
Guest Speaker Bio
Sara Rogers, PharmD, BCPS, is a Board Certified Pharmacotherapy Specialist (BCPT), researcher and nonprofit director. As a proponent of personalized medicine and preventing harm from medication use, she co-founded the American Society of Pharmacovigilance in 2018. Since there is a strong genetic component in the way that patients respond to medications, she has taken an active role in addressing barriers to widespread implementation of pharmacogenomics.
Dr. Rogers is a member of the Clinical Pharmacogenetics Implementation Consortium, Chairman of the Pharmacogenomics Access and Reimbursement Coalition, and an organizational member of the NIH National Human Genomics Research Institute (NHGRI) Inter-Society Coordinating Committee. She hopes these efforts will lead to improved health outcomes for patients across the US, regardless of socioeconomic status.
Additional Resources & Links
The American Society of Pharmacovigilance
Follow us on Social Media
About Innovation Compounding
Innovation Compounding is licensed as a 503A, compounding pharmacy, accredited by The Pharmacy Compounding Accreditation Board (PCAB®).
Today, we support over 7,000 prescribers, 70,000+ patients, and annually provide 100,000+ prescriptions to 46 states across the U.S.
We commit to individualized pharmaceutical care by being relentless in our drive for personalized medicine, compassionate toward our patients and doctors, and being a #WellnessAdvocate for our patients’ lives and state of well being.
Learn more about the work we do and how we can help to build your practice by visiting us online:Support the show